Microgravity: Developing Drugs In Space In-Orbit podcast

5d ago 38:59

Content provided by Story Ninety-Four and Satellite Applications Catapult. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Story Ninety-Four and Satellite Applications Catapult or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.

Could space be the key to better, faster drug development?

In this episode of In-Orbit, host Dallas Campbell explores how microgravity environments are reshaping the future of pharmaceuticals. With guests Dr Martin Braddock from GENIXICONSULTING and William Birch from the Satellite Applications Catapult, the discussion dives into why the absence of gravity enables better crystal growth, enhances drug discovery, and opens new possibilities for biomanufacturing in space. The episode unpacks both the science and commercial potential of conducting pharmaceutical R&D off-planet, from creating more effective drugs to future ambitions like 3D bioprinting human tissue in orbit.

The conversation doesn’t shy away from the challenges — including cost, regulatory barriers, and the need for new infrastructure. Whether you're a pharmaceutical innovator, space enthusiast, or curious about the intersection of health and space, this episode offers a fascinating glimpse into how drug development could be transformed in the next decade.

(00:00) - Welcome to In-Orbit
(00:33) - Meet the Experts: Martin and William
(03:29) - Understanding Microgravity
(06:26) - Microgravity's Impact on the Human Body
(08:47) - Crystals and Drug Design in Space
(16:16) - The Future of Pharmaceuticals in Space
(17:41) - Introduction to Space Drug Development
(17:52) - Experiments and Companies in Space
(20:03) - Challenges and Regulatory Hurdles
(21:35) - Bone Loss and Osteoporosis Drugs
(28:50) - 3D Bioprinting and Future Prospects
(32:27) - Investment and Future of Space Medicine

Dr Martin Braddock: Founder and Director of GENIXICONSULTING, with over 29 years in biopharma including roles at AstraZeneca and GlaxoSmithKline. He is a leading advocate for integrating microgravity into drug development.

William Birch: Strategic Account Director for Space at the Satellite Applications Catapult, where he connects industry players to drive R&D and economic growth in the UK space sector. Formerly worked in biomedical corporate finance with a focus on longevity research.

Satellite Applications Catapult: LinkedIn, Twitter/X, Facebook, Website

Produced by Story Ninety-Four in Oxford.

67 episodes